3Lambert BL, Lin SJ, Tan H. Designing safe drug names[J]. Drug Saf,2005,28(6) :495.
4U.S. Department of Health and Human Services. Guidance for Industry Contents of a Complete Submission for the Evaluation of Proprietary Names [ EB/OL ]. ( 2010-02 )/[ 2011-01-11 ] http://www, fda. gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM075068, pdf.
5Health Products and Food Branch. Guidance For Industry Drug Name Review : Look-alike Sound-alike (LA/SA) Health Product Names [ EB/OL ]. ( 2005-10-27 ) / [ 2011-01-10 ] http ://www. hc-sc, gc. ca/dhp-mps/brgtherap/applic-demande/guides/drugsdrogues/lasa_premkt-noms_semblables_precomm-eng, php.
6The UK's Medicines and Healthcare products Regulatory Agency Narrow therapeutic index drug: prescribe and dispense by brand name [ EB/OL ]. ( 2009-12-14 ) / [ 2011-01-10 ] http :// www. mhra. gov. uk/Safetyinformation/Safetywarningsalertsandre-calls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforheahhcareprofessionalsonthesafetyofmedicines/ CON068166.
7Filik R, Price J, Darker I, et al. The influence of tall man lettering on drug name confusion : a laboratory-based investigation in the UK using younger and older adults and healthcare practitioners[J]. Drug Saf,2010,33(8) :677.
